To cite this paper use one of the standards below:
Please log in to watch the video
Log inINTRODUCTION AND OBJECTIVES: p53 is a tumor suppressor protein mutated in more than 50% of cases of cancer. When mutated, p53 has a less stable conformation and a greater tendency to aggregate. The therapy available for the treatment of cancers in general still quite limited, and it is still necessary to study new therapeutic targets, such as the aggregated of p53 protein, as well as new molecules with anti-tumorigenic activity. Our group demonstrated that PRIMA-1, a Michael acceptor molecule that is able to bind covalently to the cysteines present in the central domain of the mutant p53 protein and stabilizing it in a wild type like conformation, is able to clear p53 aggregates. Menadione, is also a potencial michael acceptor and is a potent therapeutic molecule that inhibits the progression of Hen egg white lysozyme (HEWL) and Aβ-42 aggregation process in vitro, in addition to having anti-tumor effects. Therefore, our main objective is to investigate the effects and the molecular mechanism of action of new drug candidates who are derived from Menadione structure and are also potential Michael acceptors, as well as PRIMA-1. MATERIAL AND METHODS: Menadione and 21 new derivatives with Michael acceptor characteristics were screened through MTT reduction assay. Breast cancer cell lines expressing wild type (MCF-7) or mutant (MDA-MB-231) p53 were treated with the new compounds and analyzed by Western blotting, immunoprecipitation, flow cytometry and 3D cells assays. RESULTS AND CONCLUSION: 21 new compounds were screened using the MTT reduction assay using 10 μM in breast tumor cell lines expressing mutant p53 (MDA-MB-231) or wild type p53 (MCF-7). Three of them were selected for reducing more the cell viability of MDA-MB-231 (RCP-03, RCP-17 and RCP18), for being 10 times more potent then PRIMA-1, for be better than Menadione and more selective then Doxorubicin. Then, the MDA-MB-231 cell were treated with 10 μM of the selected compounds and their extract were immunoprecipitated with anti-amyloid oligomers antibody (A11), demonstrating that RCP 17 and 18 were able to reduce the p53 levels in the amyloid fraction. Using high-throughput screening (HTS), we also demonstrated that after treatment with 5 µM of RCP 17 the fluorescence intensity of pAB 1620, which detects wild type p53, increases, suggesting that p53 is reactivated. Functional assays were also performed with compounds RCP 17 and 18. Both compounds shown to induce apoptosis by the Annexin / PI assay, but the RCP-17 compound showed more late apoptosis. By western blotting we observed that both compounds were able to increase p21 levels. With this set of results we can demonstrate that RCP-17 and -18 are able to decrease mutant p53 R280K aggregates in MDA-MB-231 cells and are great compounds with promising antitumor effects.
Maria Gabriela Vera Lozada
Boa tarde Giulia. Meu nome é María Gabriela e estou avaliando o seu pôster.
A seguir colocarei algumas perguntas/sugestões sobre o seu trabalho:
Parabéns pelo seu trabalho
Leandro Alves
Não seria interessante comparar o resultado com uma droga referência já que você está fazendo o screening de candidatos a farmacos antitumorais? Se tiver é claro!
Giulia Ferretti
Boa Tarde Prezado Leandro Alves!
Para isso, estamos adotando algumas abordagens:
Mas com certeza sua sugestão é bastante válida e podemos pensar em estender a utilização delas em todo o processo.
Obrigada pela sugestão!
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper
Giulia Ferretti
Boa Tarde Prezada Maria Lozada. Para facilitar, vou responder na mesma ordem das perguntas feitas:
Muito Obrigada pelas perguntas!